[go: up one dir, main page]

DE122011100019I1 - Wassrige flussige zubereitung mit 2-amino-3-(4-bromobenzoyl) phenylessigsaure. - Google Patents

Wassrige flussige zubereitung mit 2-amino-3-(4-bromobenzoyl) phenylessigsaure.

Info

Publication number
DE122011100019I1
DE122011100019I1 DE201112100019 DE122011100019C DE122011100019I1 DE 122011100019 I1 DE122011100019 I1 DE 122011100019I1 DE 201112100019 DE201112100019 DE 201112100019 DE 122011100019 C DE122011100019 C DE 122011100019C DE 122011100019 I1 DE122011100019 I1 DE 122011100019I1
Authority
DE
Germany
Prior art keywords
liquid preparation
aqueous liquid
rhinitis
bromobenzoyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE201112100019
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32767329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122011100019(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Publication of DE122011100019I1 publication Critical patent/DE122011100019I1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE201112100019 2003-01-21 2004-01-16 Wassrige flussige zubereitung mit 2-amino-3-(4-bromobenzoyl) phenylessigsaure. Pending DE122011100019I1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003012427 2003-01-21
PCT/JP2004/000350 WO2004064828A1 (ja) 2003-01-21 2004-01-16 ２−アミノ−３−(４−ブロモベンゾイル)フェニル酢酸含有水性液剤

Publications (1)

Publication Number Publication Date
DE122011100019I1 true DE122011100019I1 (de) 2011-11-03

Family

ID=32767329

Family Applications (2)

Application Number Title Priority Date Filing Date
DE201112100019 Pending DE122011100019I1 (de) 2003-01-21 2004-01-16 Wassrige flussige zubereitung mit 2-amino-3-(4-bromobenzoyl) phenylessigsaure.
DE602004013420T Expired - Lifetime DE602004013420T2 (de) 2003-01-21 2004-01-16 Wässrige flüssige zubereitung mit 2-amino-3-(4-bromobenzoyl)phenylessigsäure

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602004013420T Expired - Lifetime DE602004013420T2 (de) 2003-01-21 2004-01-16 Wässrige flüssige zubereitung mit 2-amino-3-(4-bromobenzoyl)phenylessigsäure

Country Status (15)

Country Link
US (9) US8129431B2 (de)
EP (1) EP1586316B1 (de)
JP (1) JP4500261B2 (de)
KR (1) KR101059711B1 (de)
CN (1) CN100341498C (de)
AT (1) ATE393627T1 (de)
BE (1) BE2011C027I2 (de)
CA (2) CA2944832C (de)
DE (2) DE122011100019I1 (de)
ES (1) ES2301964T3 (de)
FR (1) FR11C0031I2 (de)
HU (1) HUS1100022I1 (de)
MX (1) MX2016014404A (de)
PT (1) PT1586316E (de)
WO (2) WO2004064828A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552020B1 (en) * 1999-07-30 2003-04-22 Allergan, Inc. Compositions including antibiotics and methods for using same
KR101059711B1 (ko) * 2003-01-21 2011-08-29 센주 세이야꾸 가부시키가이샤 2-아미노-3-(4-브로모벤조일)페닐아세트산 함유 수성액제
JP4933897B2 (ja) * 2004-11-05 2012-05-16 千寿製薬株式会社 眼内移行性促進水性点眼剤
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
US20100130580A1 (en) * 2006-01-25 2010-05-27 Aciex Therapeutics, Inc. Formulations and Methods for Treating Dry Eye
EP1981491A4 (de) * 2006-01-25 2009-09-23 Aciex Inc Formulierungen und verfahren zur behandlung von keratoconjunctivitis sicca
AU2008219600A1 (en) * 2007-02-28 2008-09-04 Aciex Therapeutics, Inc. Methods and compositions for normalizing meibomian gland secretions
EP2160182A1 (de) * 2007-05-24 2010-03-10 Aciex Therapeutics, Inc. Formulierungen und verfahren zur behandlung von keratoconjunctivitis sicca
CN101313899B (zh) * 2007-06-01 2012-02-29 北京德众万全药物技术开发有限公司 一种含有溴芬酸钠的眼用药物组合物
WO2009105534A2 (en) * 2008-02-21 2009-08-27 Ista Pharmaceuticals Ophthalmic nsaids as adjuvants
DK2420223T3 (da) * 2008-03-17 2017-11-06 Novartis Ag Vandige farmaceutiske sammensætninger med borat-polyol-komplekser
US8778999B2 (en) * 2009-03-05 2014-07-15 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic compositions
TWI489997B (zh) * 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
GB2484843A (en) * 2009-10-15 2012-04-25 Johnson Matthey Plc Polymorphs of Bromfenac sodium
US8299295B2 (en) 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
GB0919757D0 (en) * 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
EP2498768A1 (de) * 2009-11-11 2012-09-19 Micro Labs Limited Pharmazeutische kombination aus einer prostaglandinverbindung und nsaid zur behandlung von glaukom und augenhochdruck
CN103379904A (zh) * 2011-01-18 2013-10-30 千寿制药株式会社 具有保存效能的溴芬酸水性液剂组合物
JP6012231B2 (ja) * 2011-04-08 2016-10-25 ロート製薬株式会社 ブロムフェナク含有組成物
EP2701682A1 (de) 2011-04-29 2014-03-05 Allergan, Inc. Latanoprost-implantat aus lösungsmittelgegossener folie mit verzögerter freisetzung
US20130023575A1 (en) * 2011-07-22 2013-01-24 Kamran Hosseini Compositions and methods for the treatment of ocular surface allergies
ES2992712T3 (en) 2011-10-12 2024-12-17 Bausch & Lomb Ocular composition containing bromfenac with increased bioavailability
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
US20130165419A1 (en) * 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
CN104661682B (zh) * 2012-09-27 2018-05-11 千寿制药株式会社 水性液剂
JP6161500B2 (ja) * 2012-10-05 2017-07-12 ロート製薬株式会社 ブロムフェナク含有組成物
WO2014078766A1 (en) 2012-11-19 2014-05-22 Bausch & Lomb Incorporated Aqueous liquid composition containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
WO2014120293A1 (en) * 2013-01-31 2014-08-07 Sentiss Pharma Pvt.Ltd. Ophthalmic formulations
BR112015017919A8 (pt) 2013-01-31 2019-11-05 Senju Pharma Co preparação líquida aquosa e método para clarificar uma preparação líquida aquosa
KR20150110775A (ko) * 2013-01-31 2015-10-02 센주 세이야꾸 가부시키가이샤 안정한 수성액제
US20160143869A1 (en) 2013-06-19 2016-05-26 Sentiss Research Center Stable bromfenac solution
JP2015086222A (ja) * 2013-09-26 2015-05-07 参天製薬株式会社 安定化された２−アミノ−３−（４−ブロモベンゾイル）フェニル酢酸含有水性組成物
WO2015087267A2 (en) * 2013-12-12 2015-06-18 Sentiss Pharma Private Limited Stable bromfenac ophthalmic solution
CN104151182B (zh) * 2014-06-16 2016-03-30 广东众生药业股份有限公司 一种溴芬酸钠倍半水合物的制备方法
US11452732B2 (en) 2015-09-05 2022-09-27 Randal Davis Homogeneous ophthalmic composition
US10130639B1 (en) 2015-09-05 2018-11-20 Randal Davis Homogeneous ophthalmic composition
CN106404952B (zh) * 2016-08-31 2019-06-11 辰欣佛都药业（汶上）有限公司 一种溴芬酸钠滴眼液有关物质的测定方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2880130A (en) 1956-12-24 1959-03-31 Upjohn Co Anti-inflammatory steroid solutions
US2880138A (en) 1956-12-24 1959-03-31 Upjohn Co Anti-inflammatory steroid solutions
SE400966B (sv) * 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror
US4683242A (en) 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
GB8630273D0 (en) 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
CA1328614C (en) * 1987-09-11 1994-04-19 Cherng-Chyi Roger Fu Preservative system for ophthalmics formulations
US5414011A (en) 1987-09-11 1995-05-09 Syntex (U.S.A.) Inc. Preservative system for ophthalmic formulations
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
CA1325382C (en) * 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
JPH0283323A (ja) * 1988-09-20 1990-03-23 Zeria Pharmaceut Co Ltd 安定な酪酸リボフラビン水溶液
JPH02124819A (ja) 1988-11-01 1990-05-14 Mitsubishi Kasei Corp 経口コレステロール低下剤
JPH05223052A (ja) 1992-02-06 1993-08-31 Kanematsu Eng Kk 波浪エネルギ−を利用した電流発生装置及びこの電流発生装置が備えられた水素ガス発生装置
WO1994005298A1 (en) 1992-08-28 1994-03-17 Pharmos Corporation Submicron emulsions as ocular drug delivery vehicles
AU6021794A (en) 1993-01-11 1994-08-15 Allergan, Inc. Ophthalmic compositions comprising benzyllauryldimethylammonium chloride
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
LT3969B (en) 1994-03-15 1996-05-27 Senju Pharma Co Method for stabilizing pranoprofen and stable liquid preparation of pranoprofen
ES2079320B1 (es) * 1994-05-17 1996-10-16 Cusi Lab Disolucion oftalmica a base de un diclofenaco y tobramicina y sus aplicaciones.
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
CA2201134A1 (en) 1994-10-10 1996-04-18 Alfred Sallmann Ophthalmic and aural compositions containing diclofenac potassium
US5603929A (en) * 1994-11-16 1997-02-18 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
US5750564A (en) * 1995-09-12 1998-05-12 Hellberg; Mark Anti-oxidant esters of non-steroidal anti-inflammatory agents
US6071904A (en) * 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US5942508A (en) * 1997-02-04 1999-08-24 Senju Pharmaceutical Co., Ltd. Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid
US6274592B1 (en) * 1997-02-04 2001-08-14 Senju Pharmaceutical Co., Ltd. Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid
TW546151B (en) 1997-07-23 2003-08-11 Senju Pharma Co Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
JPH11228404A (ja) * 1997-12-11 1999-08-24 Senju Pharmaceut Co Ltd 安定な水性点眼剤
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US6162393A (en) * 1998-08-06 2000-12-19 Ndt, Inc. Contact lens and ophthalmic solutions
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6369112B1 (en) * 1998-12-15 2002-04-09 Bausch & Lomb Incorporated Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by tyloxapol
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
WO2001015677A2 (en) 1999-08-31 2001-03-08 Alcon Laboratories, Inc. Use of 5-ht1b/1d agonists to treat otic pain
NZ517556A (en) 1999-09-06 2003-08-29 Ono Pharmaceutical Co N-[o-(p-pivaloyloxybenzenesulphonyl-amino)benzoyl]glycine as preventive and therapeutic agents for eye diseases
AR030345A1 (es) 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes relacionados con angiogenesis
JP2002308764A (ja) * 2001-02-09 2002-10-23 Taisho Pharmaceut Co Ltd 眼科用医薬組成物
KR101059711B1 (ko) * 2003-01-21 2011-08-29 센주 세이야꾸 가부시키가이샤 2-아미노-3-(4-브로모벤조일)페닐아세트산 함유 수성액제
ATE552838T1 (de) * 2003-11-14 2012-04-15 Senju Pharma Co Wässrige lösung mit aminoglykosid-antibiotikum und bromfenac
JP5223052B2 (ja) 2010-05-21 2013-06-26 春誠 鈴木 コーキングガン
ES2992712T3 (en) * 2011-10-12 2024-12-17 Bausch & Lomb Ocular composition containing bromfenac with increased bioavailability
WO2014078766A1 (en) * 2012-11-19 2014-05-22 Bausch & Lomb Incorporated Aqueous liquid composition containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid

Also Published As

Publication number Publication date
FR11C0031I2 (fr) 2012-03-16
US20140243413A1 (en) 2014-08-28
CN1700913A (zh) 2005-11-23
KR101059711B1 (ko) 2011-08-29
US9144609B2 (en) 2015-09-29
WO2004064828A1 (ja) 2004-08-05
EP1586316B1 (de) 2008-04-30
US8927606B1 (en) 2015-01-06
US8497304B2 (en) 2013-07-30
US20150025149A1 (en) 2015-01-22
ATE393627T1 (de) 2008-05-15
CA3043910A1 (en) 2015-11-12
KR20050092691A (ko) 2005-09-22
DE602004013420T2 (de) 2009-06-04
CA2944832C (en) 2019-10-08
US20050239895A1 (en) 2005-10-27
US20140235721A1 (en) 2014-08-21
US20070287749A1 (en) 2007-12-13
US20140142183A1 (en) 2014-05-22
CN100341498C (zh) 2007-10-10
US20130090384A1 (en) 2013-04-11
JPWO2004064828A1 (ja) 2006-05-18
WO2015170177A1 (en) 2015-11-12
US8129431B2 (en) 2012-03-06
DE602004013420D1 (de) 2008-06-12
HK1083468A1 (en) 2006-07-07
BE2011C027I2 (de) 2023-03-07
US8754131B2 (en) 2014-06-17
EP1586316A1 (de) 2005-10-19
ES2301964T3 (es) 2008-07-01
MX2016014404A (es) 2017-10-27
US20150011634A1 (en) 2015-01-08
JP4500261B2 (ja) 2010-07-14
US20120115957A1 (en) 2012-05-10
PT1586316E (pt) 2008-05-28
US8871813B2 (en) 2014-10-28
US8669290B2 (en) 2014-03-11
CA2944832A1 (en) 2015-11-12
EP1586316A4 (de) 2007-06-27
US9561277B2 (en) 2017-02-07
HUS1100022I1 (hu) 2017-04-28

Similar Documents

Publication Publication Date Title
ATE393627T1 (de) Wässrige flüssige zubereitung mit 2-amino-3-(4- bromobenzoyl)phenylessigsäure
RU2010139958A (ru) Стабилизированная фармацевтическая композиция, cодержащая доцетаксель
CY1123724T1 (el) Φαρμακευτικη συνθεση για τροποποιημενη αποδεσμευση
FR18C1027I1 (fr) Composition fongicide contenant un derive d'amide d'acide
ATE532797T1 (de) Polymerisierbare zusammensetzungen enthaltend salze aus barbitursäure-derivaten
CY1112401T1 (el) Παραγωγα πυριδαζινης
NO20044406L (no) Stabilisert flytende farmasoytisk sammensetning samt fremgangsmate for a oke stabiliteten av IL-2
RU2011101713A (ru) Фармацевтическая композиция
BR112015005995A2 (pt) formulações líquidas de apixaban
CY1116189T1 (el) Σταθερη υγρη φαρμακευτικη συνθεση με βαση την τραζοδονη
FR2933006B1 (fr) Solution absorbante contenant un inhibiteur de degradation soufre a groupement carboxyle et methode pour limiter la degradation d'une solution absorbante
IS8231A (is) Lyfjafræðilega gagnleg sölt karboxýlsýruafleiða
DE602006000874D1 (de) Wässrige Zusammensetzungen enthaltend Salze von Perfluoropolyether Dicarbonsäuren zur ölabstossenden Papierleimung
EA200501789A1 (ru) Стабильный водный раствор эритропоэтина человека, не содержащий сывороточного альбумина
DK1853279T3 (da) Amid-derivater af hyaluronsyre i osteoarthrose
DK1459739T3 (da) Ikke-hydroskopiske farmaceutiske sammensætninger indeholdende ikke-hydratiserede quinolin-carboxylsyrer
DE602004009573D1 (de) Herstellung von 5-methyl-dihydrofuran-2-on aus levulinsäure in superkritischen medien
EA201490127A1 (ru) Офтальмологический раствор, содержащий гиалуроновую кислоту или ее соль и пропиленгликоль
CY1112285T1 (el) Υγρες φαρμακοτεχνικες μορφες αλατων 4-[2-(4-μεθυλφαινυλσουλφανυλ)φαινυλ]πιπεριδινης
MA30600B1 (fr) Formulation medicamenteuse aqueuse d'acide 4-[((4-carboxybutyl)-{2-[(4-phenethyl-benzyl)oxy]-phenethyl}amino)methyl]benzoique.
BRPI0814580A2 (pt) Utilização de pelo menos um derivado de oxima da colest-4-en-3-ona ou um dos seus sais de adição com ácidos aceitáveis, ou de um dos seus ésteres ou de um dos sais de adição dos referidos ésteres com os ácidos aceitáveis
WO2015087267A3 (en) Stable bromfenac ophthalmic solution
EP2284211A4 (de) Wasserhaltige emulsion mit einem a-olefin-/(meth)acrylat-copolymer und verfahren zu ihrer herstellung
EA201791191A1 (ru) Водные фармацевтические композиции для местного применения в ротовой полости, содержащие флурбипрофен и декспантенол
FR2933002B1 (fr) Solution absorbante contenant un inhibiteur de degradation soufre derive d'un acide amine et methode pour limiter la degradation d'une solution absorbante